In particular, multiple linear regression analyses (all immunoreactivity levels were square-root transformed to improve normality unless stated otherwise) indicated that while adenomyosis induction was associated with the increase (decrease for PR-B) while Ozagrel treatment or platelet depletion was associated, in a dose-dependent manner, with a significant reduction (increase for PR-B) of immunoreactivity to all these proteins or the extent of platelet aggregation/macrophage infiltration (all p-values <0.01, with R2 ranging from 0.31 to 0.76; Table 1 and Fig. 5). The gene discussed is RB1; the disease is adenomyosis.